{
    "organizations": [],
    "uuid": "6a27d1746d71bc9fc83850b5dc8bd3135b29d944",
    "author": "",
    "url": "https://www.reuters.com/article/brief-morphotek-announces-agreement-to-l/brief-morphotek-announces-agreement-to-license-its-eribulin-linker-payload-to-bliss-biopharmaceutical-of-china-idUSFWN1RM0P9",
    "ord_in_thread": 0,
    "title": "BRIEF-Morphotek Announces Agreement To License Its Eribulin-Linker Payload To Bliss Biopharmaceutical Of China",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9, 2018 / 2:55 PM / Updated 22 minutes ago BRIEF-Morphotek Announces Agreement To License Its Eribulin-Linker Payload To Bliss Biopharmaceutical Of China Reuters Staff \n* LICENSED ITS ERIBULIN-LINKER PAYLOAD TO BLISS BIOPHARMACEUTICAL CO OF CHINA \n* LICENSING AGREEMENT WITH BLISSBIO INCLUDES UPFRONT PAYMENT, MILESTONES, SALES ROYALTY PAYMENTS, WHICH ARE UNDISCLOSED \n* BLISSBIO HAS EXCLUSIVITY OPTION TO EXPAND TERRITORY BEYOND CHINA & TO DEVELOP THERAPEUTIC ADCS TO 2 ADDITIONAL ONCOLOGY TARGETS \n* AGREEMENT GRANTS BLISSBIO EXCLUSIVE RIGHT TO USE ERIBULIN-LINKER PAYLOAD TO DEVELOP THERAPEUTIC ADC AGAINST ONCOLOGY TARGET FOR CHINA MARKET Source text for Eikon: Further company coverage:",
    "published": "2018-04-09T17:52:00.000+03:00",
    "crawled": "2018-04-09T18:17:40.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "agreement",
        "license",
        "payload",
        "bliss",
        "biopharmaceutical",
        "china",
        "reuters",
        "staff",
        "licensed",
        "payload",
        "bliss",
        "biopharmaceutical",
        "co",
        "china",
        "licensing",
        "agreement",
        "blissbio",
        "includes",
        "upfront",
        "payment",
        "milestone",
        "sale",
        "royalty",
        "payment",
        "undisclosed",
        "blissbio",
        "exclusivity",
        "option",
        "expand",
        "territory",
        "beyond",
        "china",
        "develop",
        "therapeutic",
        "adcs",
        "additional",
        "oncology",
        "target",
        "agreement",
        "grant",
        "blissbio",
        "exclusive",
        "right",
        "use",
        "payload",
        "develop",
        "therapeutic",
        "adc",
        "oncology",
        "target",
        "china",
        "market",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}